SEC Form 4 · accession 0001144204-15-068187
Akari Therapeutics Plc · AKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark S Cohen
Director
Period of report
Nov 25, 2015
Accepted (ET)
Nov 25, 2015 · 6:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001541157
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Ordinary SharesF1 | $0.1917 | Nov 25, 2015 | A | 1,028,722 | A | Nov 25, 2016 | Nov 25, 2025 | Ordinary Shares | 1,028,722 | 1,028,722 | D |
Explanation of responses
- F1All shares underlying the options will vest in three equal annual installments beginning on November 25, 2016 and expire ten years from issuance.